BioCatalystWatch
CRMDWorkspace / CRMD / OverviewCompany library
Price
Market cap
Next catalystAdditional DefenCath RWE data during 2026 / 1H 2027DefenCath — hemodialysis CRBSI prevention · Data readoutCompany presentation ↗
Cash

Chart & Events

Candle interval

Core Clinical

DefenCath

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

DefenCath

PreINDP1P2P3FilingApproved
Upcoming / outlook

REZZAYO (rezafungin)

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

DefenCath

PreINDP1P2P3FilingApproved
Upcoming / outlook

REZZAYO (rezafungin)

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

DefenCath

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Other pipelines

Approved / commercial

REZZAYO (rezafungin)

Approved

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Operating
Investing
Financing

Reported shares and borrowings

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

CRMD PR & News

PR & News

CRMD SEC archive